Welcome to our dedicated page for RAPID MICRO BIOSYSTEMS SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes reported an automatic sale of 7,480 shares of Class A Common Stock. The shares were sold at an average price of $4.3181 per share to cover tax obligations arising from the vesting of restricted stock units. After this tax-related sale, he directly holds 556,194 shares, indicating he retains a substantial equity position in the company.
RAPID MICRO BIOSYSTEMS, INC. president and CEO Robert G. Spignesi Jr. reported an automatic sale of 17,922 shares of Class A common stock at $4.1115 per share on March 10, 2026.
The footnote explains this sale was made solely to cover tax obligations related to the vesting of restricted stock units. After the transaction, he directly owned 1,169,848 shares, indicating this was a small, routine disposition relative to his overall stake.
Rapid Micro Biosystems filed its annual report describing a business focused on automating microbial quality control in pharmaceutical manufacturing through its Growth Direct platform. The system replaces manual plate handling and visual colony counting with robotic automation, optical imaging and vision algorithms, targeting faster, more accurate and data-secure testing.
The company reports a large addressable market, estimating approximately $5.0 billion for system sales and a further $5.0 billion for recurring consumables and services. As of December 31, 2025, it had incurred an accumulated deficit of $522.4 million, including a net loss of $47.1 million for 2025 versus $46.9 million for 2024.
Rapid Micro Biosystems highlights positive gross margins in 2025 after prior investments in manufacturing and service infrastructure, but warns it may continue to incur losses and may need additional capital. It emphasizes growth initiatives around biologics and cell and gene therapies, a new rapid sterility test, integration with Lonza’s MODA-EM module, and a global distribution and collaboration agreement with MilliporeSigma that includes minimum system purchase commitments and potential supply-chain cost savings.
Rapid Micro Biosystems reported record 2025 results with continued losses but improving scale. Total revenue reached $33.6 million in 2025, up 20% from 2024, with fourth quarter revenue of $11.3 million, a 37% increase year over year. Product revenue grew to $23.4 million for the year, while recurring revenue rose to $17.8 million.
Full-year gross margin improved to 3% from 0% in 2024, or 6% on a non-GAAP basis excluding a write-off of unusable inventory and related warranty expense. Net loss was $47.1 million, similar to $46.9 million in 2024, as operating expenses fell 3% to $48.4 million.
The company highlighted record multi-system orders from Amgen in late 2025 and a follow-on multi-system order from Samsung Biologics in early 2026, underscoring broader adoption of its Growth Direct platform. For 2026, it expects total revenue of $37.0 million to $41.0 million, 30 to 38 Growth Direct system placements and gross margin of approximately 20%.
Sean M. Wirtjes reported sales of Class A shares and a planned sale tied to restricted stock vesting. The filing shows sale of 6,027 Class A shares on 02/09/2026 for $22,798.33 and 17,254 Class A shares on 02/20/2026 for $67,687.44. It also lists 7,480 Class A shares to be sold on 03/10/2026 related to Restricted Stock Vesting.
RPID submitted a Rule 144 notice proposing the sale of 9,603 Class A shares through Fidelity Brokerage Services LLC. The shares were recorded as restricted stock vesting on 03/10/2026 and listed as compensation. The filing also lists prior dispositions by John Wilson: 4,610 shares on 02/09/2026 and 5,403 shares on 02/20/2026, with corresponding dollar figures shown in the excerpt.
Robert G. Spignesi filed a Form 144 notifying a proposed sale of 17,922 Class A shares arising from restricted stock vesting on 03/09/2026.
The notice also reports prior sales of 12,840 Class A shares on 02/09/2026 for $48,569.87 and 38,327 Class A shares on 02/19/2026 for $148,911.89. Shares outstanding were reported as 39,823,026 as of 03/10/2026.
RAPID MICRO BIOSYSTEMS, INC. director Natale S. Ricciardi exercised a stock option and acquired Class A common shares. On February 27, 2026, he exercised an option for 842 shares at an exercise price of $0.75 per share. Following the exercise, his direct holdings of Class A common stock increased to 29,442 shares. The footnote indicates the option was already fully vested and exercisable, meaning this transaction reflects the use of an existing equity award rather than a new grant or open-market purchase.
RAPID MICRO BIOSYSTEMS, INC. chief operating officer John J. Wilson reported an automatic sale of 5,403 shares of Class A common stock at $3.923 per share. According to the footnote, this sale was made solely to cover tax obligations tied to vesting restricted stock units. After the transaction, he directly held 326,365 shares of Class A common stock.
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes reported an automatic sale of Class A common stock to cover taxes tied to restricted stock unit vesting. He sold 17,254 shares at an average price of $3.923 per share. After this tax-related sale, he continues to hold 563,674 shares directly.